What does this research mean for the field?

The use of fluid biomarkers in Alzheimer's disease treatment decisions presents multiple ethical concerns, with risks currently outweighing benefits due to uncertainty in biomarker performance, particularly among underrepresented groups. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the ethical considerations of utilizing fluid biomarkers to determine treatment eligibility for individuals with Alzheimer's disease and mild cognitive impairment.

September 2, 2026Aging & Mental HealthOpen Access

Ethical considerations of fluid biomarker use in alzheimer’s disease - a rapid review

View Full Paper

Ask AI

Bookmark

Authors

FFFaye Forsyth ADAna Diaz‐Ponce VAVebjørn Andersson

Discussion

Member takes

Overview

Rapid review reveals substantial ethical risks over benefits in Alzheimer's disease biomarker testing, highlighting major uncertainties in clinical utility and health equity.

Key Points

To evaluate the ethical considerations of utilizing fluid biomarkers to determine treatment eligibility for individuals with Alzheimer's disease and mild cognitive impairment.
Conducted a rapid review adhering to established methodological guidelines and PRISMA reporting standards.
Identified and screened 10,611 records across medical databases, including 34 publications for final synthesis.
Extracted and mapped evidence across the four core pillars of biomedical ethics using narrative synthesis.
Identified that ethical risks currently outweigh tangible benefits in clinical practice, driven largely by a lack of empirical evidence supporting biomarker use.
Observed that performance uncertainty in underrepresented groups threatens patient autonomy, justice, and non-maleficence during treatment decision-making.

Cite This Study

Forsyth et al. (2026) studied this question.

synapsesocial.com/papers/6a97e237c562ede874ec63e5 https://doi.org/10.1080/13607863.2026.2719938

View Full Paper

Ask AI

Bookmark

September 2, 2026Aging & Mental HealthOpen Access

Ethical considerations of fluid biomarker use in alzheimer’s disease - a rapid review

View Full Paper

Ask AI

Bookmark

Authors

FFFaye Forsyth ADAna Diaz‐Ponce VAVebjørn Andersson

Discussion

Member takes

Overview

Rapid review reveals substantial ethical risks over benefits in Alzheimer's disease biomarker testing, highlighting major uncertainties in clinical utility and health equity.

Key Points

To evaluate the ethical considerations of utilizing fluid biomarkers to determine treatment eligibility for individuals with Alzheimer's disease and mild cognitive impairment.
Conducted a rapid review adhering to established methodological guidelines and PRISMA reporting standards.
Identified and screened 10,611 records across medical databases, including 34 publications for final synthesis.
Extracted and mapped evidence across the four core pillars of biomedical ethics using narrative synthesis.
Identified that ethical risks currently outweigh tangible benefits in clinical practice, driven largely by a lack of empirical evidence supporting biomarker use.
Observed that performance uncertainty in underrepresented groups threatens patient autonomy, justice, and non-maleficence during treatment decision-making.

Cite This Study

Forsyth et al. (2026) studied this question.

synapsesocial.com/papers/6a97e237c562ede874ec63e5 https://doi.org/10.1080/13607863.2026.2719938

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark